Find a Physician | How to Contribute | About Us | Clinical Trials
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU FC11S02

Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma (OER-SAR-043)
Principal Investigator
Mark Agulnik
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU FC11S02
The goal of this study is to find out what effects, good and/or bad, pazopanib has on patients and their angiosarcoma.
The standard treatment for angiosarcoma is surgery to remove the cancer; however, these tumors have a high chance of returning, leading to the need for systemic therapy. Few effective systemic therapy options exist for angiosarcoma. Pazopanib is a drug that has shown encouraging activity in previous studies of other types of sarcomas. In laboratory testing pazopanib has shown anti-angiogenic effects (it stops or slows the growth of blood vessels to the cancer). Other drugs that have anti-angiogenic effects have been effective in fighting angiosarcoma, so researchers hope that pazopanib will have therapeutic activity in this disease.
Some of the eligibility criteria include:
  • Participants must have angiosarcoma that cannot be removed with surgery.
  • Participants must have had at least one prior treatment regimen for their angiosarcoma.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants in this study will take pazopanib pills by mouth every day until the pills stop working or until the participant has too many side effects.
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Mark Agulnik

last updated: 05-Oct-15 01:47 PM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.